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Abstract 
Cancer diagnosis at an early stage increases the chance of curative treatment and of survival. It has 
been suggested that delays on the pathway from first symptom to diagnosis and treatment may be 
socio-economically patterned, and contribute to socio-economic differences in receipt of treatment 
and in cancer survival. 
This review aimed to assess the published evidence for socio-economic inequalities in stage at 
diagnosis of lung cancer, and in the length of time spent on the lung cancer pathway. MEDLINE, 
EMBASE and CINAHL databases were searched to locate cohort studies of adults with a primary 
diagnosis of lung cancer, where the outcome was stage at diagnosis or the length of time spent 
within an interval on the care pathway, or a suitable proxy measure, analysed according to a 
measure of socio-economic position. Meta-analysis was undertaken when there were studies 
available with suitable data.  
Of the 461 records screened, 39 papers were included in the review (20 from the UK) and seven in a 
final meta-analysis for stage at diagnosis. There was no evidence of socio-economic inequalities in 
late stage at diagnosis in the most, compared to the least, deprived group (odds ratio=1.04, 95% 
confidence interval = 0.92 to 1.19). No socio-economic inequalities in the patient interval or in time 
from diagnosis to treatment were found. 
Socio-economic inequalities in stage at diagnosis are thought to be an important explanatory factor 
for survival inequalities in cancer. However, socio-economic inequalities in stage at diagnosis were 
not found in a meta-analysis for lung cancer.  
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BACKGROUND 
Cancer patients who are diagnosed at an early stage are more likely to be suitable for receipt of 
potentially curative treatment, thus improving their chances of survival. Length of time to diagnosis 
and treatment has also been associated with cancer survival (1). Delays may lead to diagnosis at a 
later disease stage, resulting in ‘potentially-avoidable’ deaths (2). To address this, the National 
Awareness and Early Diagnosis Initiative (NAEDI) scheme was launched in England, in order to 
encourage early presentation of patients to primary care and to improve general practitioner (GP) 
cancer recognition and referral (2).  
Lung cancer is the most common cancer, worldwide. In the USA and the UK it is the second most 
incident cancer (3, 4), as well as the most common cause of cancer mortality (4, 5). In the UK fewer 
than 10% of those diagnosed with lung cancer survive for 5 years (6).  
A socio-economic gradient for lung cancer survival (7) exists in the UK, which is not fully accounted 
for by the socio-economic gradient in incidence. Socio-economic inequalities in receipt of lung 
cancer treatment have been shown in a recent systematic review and meta-analysis (8) and there is 
some evidence that inequalities in treatment contribute to socio-economic inequalities in lung 
cancer survival (9, 10). It has also been suggested that inequalities in stage at diagnosis and in time 
to diagnosis and treatment might contribute to socio-economic differences in cancer survival (2). 
However, there has been no systematic examination of whether there are socio-economic 
inequalities in stage at diagnosis and time to treatment for lung cancer and where on the pathway 
from symptom-onset to treatment these inequalities might arise.  
This review aimed to investigate whether there are socio-economic inequalities in stage at diagnosis 
for lung cancer, and in the duration of intervals (patient, primary care, referral, diagnosis, treatment) 
on the diagnostic and treatment pathway. 
METHODS/DESIGN 
A protocol was developed, registered with PROSPERO (11) and published (12). Systematic methods 
were used to identify relevant studies, assess study eligibility for inclusion and evaluate study 
quality. The review is reported according to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) guidelines (13) (see Appendix S1 for PRISMA checklist).  
Search strategy 
A search was undertaken to locate all studies published by the initial search date (Jan 2014), with a 
title and abstract published in English, examining differences, by socio-economic position (SEP), in 
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stage at diagnosis and in patient, primary care, referral, diagnostic and treatment time intervals (and 
combinations thereof) on the care pathway for lung cancer. The searches were re-run in Feb 2016 
and any further studies retrieved for inclusion. 
One researcher (LF) developed the search strategy (File S2), which was refined with the help of an 
Information Scientist and used to search the online databases of MEDLINE, EMBASE and CINAHL. 
The search terms were adapted for the different databases. Additional studies were identified by 
reviewing the reference lists of all included studies and by using a forward citation search to identify 
more recent studies that had cited included studies. EndNote X5 software was used to manage the 
references. 
Study Eligibility 
The following types of study were deemed eligible for inclusion: cohort studies of adult participants 
who had a primary diagnosis of lung cancer (small-cell lung cancer or non-small-cell lung cancer - 
ICD10 C 33 C34); published in a peer-reviewed journal up to the date that the search was run and 
where the outcome was: 
 Stage at diagnosis or stage at the start of treatment (14) [primary outcome]  
 OR mean or median time within an interval on the pathway from first symptom to treatment 
(or a suitable proxy measure of this); Or the likelihood (odds ratio[OR] or hazard ratio [HR] 
with 95% confidence intervals [CI]) of longer or shorter time within an interval on the 
pathway [secondary outcome];   
 And where outcome was analysed by a measure of SEP (an individual or area-based measure 
of deprivation, poverty, income or education). 
 
Time interval definition 
The following four time points have been identified as important markers on the cancer pathway: 
date of first symptom onset, date of first presentation to a health care professional, date of referral 
to secondary/specialist care and date of diagnosis (15).  These and other time points such as date of 
first secondary (specialist) care investigation/first hospital appointment, and date of first treatment 
can be used to define 15 interim time intervals (designated T1-T15) on the pathway from first 
symptom to diagnosis and treatment (16). 
These time intervals can be categorised as follows: patient interval (time from date of first symptom 
to date of first presentation; T1); primary care interval (date of first presentation to date of first 
investigation referral; T6); referral interval (date of GP referral to first specialist appointment or 
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investigation; T10); diagnostic interval (date of secondary care investigation to diagnosis T13); and 
treatment interval (diagnosis to treatment; T15) (12), and combinations thereof. 
The following were included as potential proxy measures of length of time intervals on the pathway; 
type of referral (urgent v routine) (17); emergency presentation (18); diagnosis at death; and 
number of pre-referral consultations (19). 
Stage definition 
Lung cancer stage can be categorised as I, II, III, IV, assigned using the TNM staging system (20). 
Papers which recorded stage at diagnosis or stage at start of treatment in this way, or as early or late 
stage, or as local, regional and distant stage, were considered for inclusion in the stage analysis. 
Study Selection and Data Extraction 
Studies obtained from the database searches were independently assessed by two researchers (LF 
and SS) in three phases: title, abstract and full paper screening,  as detailed in the protocol (12). Any 
disagreements at any of the screening stages were resolved by discussion between the two 
researchers in the first instance. A third reviewer (JA) was available to independently review the 
title, abstract or full paper, if required. 
Data extraction was carried out by LF using a pro-forma based on previous work (8). Data from a 
random sample of 10% of included papers were checked by SS, selected using a random number 
generator.  
Insurance status is an important factor relating to access to lung cancer care in the US healthcare 
system (21) and so may impact on time-intervals on the care pathway. Therefore, as in a previous 
lung cancer systematic review,(8) studies were split into three categories: those carried out in a 
healthcare system free at the point of access (a universal health care system (UHCS) similar to the 
UK); those based on an insurance system (similar to the USA); and those that include a mixture of 
free care and social insurance-based payment (some European systems).  
Study Quality 
A study quality checklist, adapted from existing quality tools (8, 15), was used to divide studies into 
eight quality categories, with 1 being the lowest, and 8 the highest quality (appendix S3). 
Cohort studies reporting only univariable analysis are of lower quality, in terms of their ability to 
control for confounding. Only studies conducting multivariable analysis (quality scores 3-8) were 
considered for meta-analysis.  
6 
 
Statistical analysis 
All studies that met the inclusion criteria were included in a narrative synthesis. Studies were 
analysed in three categories: stage at diagnosis, time interval (with sub-group analyses by interim 
intervals), and proxy time interval measures. 
Studies were considered eligible for inclusion in meta-analysis if: multivariable analysis was 
conducted (and included control for a minimum of age and sex as confounders); OR/HRs and 95% CIs 
of likelihood of earlier or later stage at diagnosis or longer or shorter time within an interval on the 
pathway (or a suitable proxy measure of this) in low compared to high SEP were calculated; and SEP 
was not further stratified by another variable.  Sub-group analyses by healthcare system category 
were conducted if two or more comparable studies per system were available.  
Random effects meta-analysis of eligible studies was undertaken using Cochrane Collaboration 
Review Manager 5.1. Natural logs of the ORs and their standard errors (SEs) were calculated for use 
in Forest plots. Where a study reported the most deprived class as the comparator then reverse ORs 
were calculated prior to meta-analysis. The I2 statistic was used to assess heterogeneity. 
Multiple papers using the same or overlapping study data were considered for inclusion. Sensitivity 
analyses were undertaken to examine the effect of including all potentially-eligible studies or only 
high quality studies in meta-analyses. However, only data from the better quality or more detailed 
paper in each overlapping study group were included in the final meta-analyses.  
RESULTS 
A total of 39 papers (14, 18, 22-58) met the inclusion criteria (table S1) and were included in the 
review (PRISMA flow diagram, Figure 1). Twenty papers used data from the UK, 10 from the USA, 2 
from Canada, 2 from Denmark and 1 each from Sweden, Australia, Italy, Korea and New Zealand. 
Twenty nine papers used data from healthcare systems free at point of access and 10 from 
insurance-based systems.  Of the 39 papers, 23 examined stage at diagnosis, 12 examined time 
intervals (three studies looked at both time intervals and stage at diagnosis), and eight examined 
potential proxy measures of delay. Some studies examining stage at diagnosis were suitable for 
meta-analysis.  
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Stage at diagnosis 
Of the 23 studies that examined socio-economic inequalities in stage at diagnosis, 16 studies 
contained data that were unsuitable for meta-analysis (one reported ORs but examined SEP 
subdivided by race, one calculated univariable ORs, and 14 did not calculate odds ratios - nine 
presented unadjusted rates (five with statistical tests) and five presented no numbers (table S4). Of 
these 16 studies, 12 reported or appeared to show no association, and 3 reported an association 
between SEP and stage at diagnosis, but not all in the same direction. One Scottish study (28) found 
that rates of early stage cancer were higher in more deprived patients than less deprived.  Similarly, 
a US study (54) found that college graduates were more likely to be diagnosed with advanced stage 
at diagnosis compared to those without a college degree, but income was not associated with stage. 
However, in contrast, a further US study (36) reported that a higher percentage of more deprived 
patients were diagnosed with later stage cancer (but no numbers presented).  
Eight studies (nine outcomes) conducted multivariable analysis and examined the likelihood (OR) of 
later (or earlier stage) at diagnosis by a marker of SEP and so were considered for meta-analysis 
(table S5). Of these, two studies looked at the same population and one study looked at the same 
outcome using two different measures of SEP (education and income). Seven studies (seven 
outcomes) with non-overlapping populations were selected for the final meta-analysis.  
Overall, there was no evidence of socio-economic inequalities in late stage at diagnosis in the most, 
compared to the least, deprived groups (n=7, odds ratio=1.04, 95% confidence interval = 0.92 to 
1.19) (Fig 2). In sub-group analysis by healthcare system, although there was no evidence of 
differences by SEP in UHCS, there was some suggestion that more deprived patients were likely to 
present with more advanced stage cancer in non-UHCS, although only 2 studies were included. 
Sensitivity analyses including all studies with overlapping populations, utilising a different measure 
of SEP, or different combinations of these, also found no association (appendix S6).  
Time intervals 
Twelve studies examined inequalities within eight of the 15 time intervals. No studies were found 
that examined the intervals from symptom onset to FHA (T3) or to treatment (T5) or from patient 
presentation to GP referral, FHA, diagnosis or treatment (T6-T9), or FHA to treatment (T14). 
Summary interval results are shown in Fig 3 and detailed results for each interval presented in 
supplementary tables 7-10. 
Two studies examined the time from symptom recognition to presentation (T1 patient interval). 
Socioeconomic position was not associated with length of patient interval in any of these (table S7). 
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The intervals from first symptom to GP referral (T2), and to diagnosis (T4), were examined in one 
study, and again no socio-economic inequalities in time intervals were found (table S7).  
Two studies examined the referral interval (T10). One found socioeconomic inequalities in time from 
GP referral to FHA with more deprived patients less likely to have a FHA within 14 days of referral, 
using cancer registry data. The other used self-reported patient survey data and no association 
between referral interval and SEP was found (table S8).  
Four studies (10 outcomes) examined time from GP referral to diagnosis (T11; table S8). In one 
study, the more highly educated (2 outcomes) were less likely to have delayed diagnosis but no 
association was found with income (2 outcomes). The other good quality study found no association 
and the remaining two studies only reported univariable analyses and did not clearly report tests of 
statistical significance. One of these analysed data from early and late stage patients separately: 
more deprived early stage patients had longer time from referral to diagnosis than less deprived 
patients (32 compared to 17 days, although no formal statistical tests were reported). No difference 
in the time between referral to diagnosis between more and less deprived patients with late stage 
disease were found. 
Two studies examined socioeconomic inequalities in time from GP referral to treatment (T12) but 
none were found (table S8).  
Three studies examined time from FHA to diagnosis and none found an association with SEP (T13; 
table S9). Five studies (eight outcomes) examined socioeconomic inequalities in time from diagnosis 
to treatment (T15) but inequalities in the treatment interval were not found (table S10). 
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Other measures  
Eight studies looked at the following measures that might be considered as consequences of delay: 
acute presentation, emergency admission, number of times to consult, and diagnosis at death. More 
deprived patients were more likely to present and to be admitted as an emergency, but socio-
economic inequalities were not found in number of times to consult or in diagnosis at death (table 
S11). 
DISCUSSION 
Principal Findings 
This is the first systematic review to explore socio-economic inequalities in stage at diagnosis and in 
duration of intervals on the diagnostic and treatment pathway of lung cancer. Thirty nine studies 
met the inclusion criteria, 23 examined stage at diagnosis (eight of which were suitable for meta-
analysis), 12 examined time intervals, and eight examined proxy measures of delay. There was no 
evidence of socio-economic inequalities in late stage at diagnosis in the most, compared to the least, 
deprived group overall and in studies from countries with UHCSs. However, there was evidence that 
more deprived patients were more likely to present as emergencies. There was some suggestion of 
socio-economic inequalities in stage at diagnosis in studies from countries with non-UHCSs with 
those in more deprived groups more likely to be diagnosed at late stage than others. No evidence of 
socio-economic inequalities in the patient or treatment intervals were found, and no consistent 
pattern was observed in diagnostic or referral intervals. No studies examined the primary care 
interval. 
Interpretation of results and comparison to previous findings 
Surgery with curative intent is only suitable for early stage lung cancer patients (59) and if patients 
with lower SEP are more likely to present later, and with later stage disease, this may help explain 
known socioeconomic inequalities in receipt of lung cancer surgery (8). In this review, however, 
presentation with later stage lung cancer in more deprived patients was not seen and so inequalities 
in stage at diagnosis cannot explain inequalities in surgery. This concurs with results from our review 
on socioeconomic inequalities in lung cancer treatment, where the association between SEP and 
receipt of surgery was independent of stage at diagnosis. When receipt of treatment was examined 
in studies of early-stage patients only, low SEP remained associated with reduced likelihood of 
surgery (8).  
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Diagnostic delay has been implicated as a factor that contributes to the poorer survival of UK cancer 
patients compared to the European average (2). However, the impact of delay on lung cancer 
survival is unclear (60) and some studies suggest that those who experience shorter system delay 
may have poorer lung cancer survival  as they are clinically “sicker”, with more obvious symptoms 
that result in urgent referral, diagnosis and treatment (1). More deprived patients have been shown 
to have higher comorbidity (34). A recent UK study, which found that lung cancer patients who were 
more clinically unwell were referred, diagnosed and treated more quickly, suggested that this ‘sicker 
quicker’ effect may act to effectively cancel out socio-economic related delays that might otherwise 
result in longer time intervals for more deprived patients (34). Very few of the studies included in 
this current review took account of patient health status when examining time intervals and lack of 
control for this major confounder may mask any inequalities that are present. 
 Strengths and weaknesses of the review and of the available evidence 
No previous reviews have systematically assessed socioeconomic inequalities in stage at diagnosis 
and in time intervals on the lung cancer care pathway and few have considered equity in a meta-
analysis. Extensive searches were carried out to identify studies in the published literature. However, 
it is possible that not all relevant studies were obtained. 
Although a number of studies examined stage at diagnosis, very few good quality studies examined 
comparable intervals on the lung cancer diagnostic and treatment pathway, meaning that meta-
analysis was only possible for studies examining stage at diagnosis. The included studies reported 
observational data only. The suitability of meta-analysis for observational studies has been 
questioned, as it may produce precise but spurious results (61). Heterogeneity can be considered 
high at >50% (62). Study heterogeneity was taken into account. Separate analyses by healthcare 
system type were carried out and different effects were found. 
There was population overlap between some datasets. We attempted to include only substantially 
non-overlapping datasets within the final meta-analysis to ensure independence of results. A 
judgement had to be made as to which was the best quality and most appropriate paper to include, 
but sensitivity analyses using different inclusion combinations (Appendix a) did not change the 
overall findings and nor did including all suitable studies, regardless of population overlap. 
A number of different measures of SEP were used in included studies. These likely categorise 
different people, and different proportions of the population, into the most and least deprived 
groups, meaning that similar populations are not always being compared across studies. This is a 
recognised problem in equity reviews (8). Most UK studies employ deprivation-index measures of 
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SEP, whereas US-based studies rely more on income-based measures.  However, across all included 
cases, area-based measures of SEP were common. These may not accurately reflect individual-level 
circumstances (63) leading to error, and possible bias. This may mean we have under-estimated the 
strength of the true association between SEP and both stage and intervals. Many included studies 
used cohort or cancer registry data not specifically collected to study socio-economic inequalities, 
meaning that authors of studies included in the review were working with the best available data for 
secondary analysis. Effort should be made to ensure household, or individual-level, markers of SEP 
are included in cohort studies and cancer registry datasets to facilitate future analyses. 
In the UK only around 20% of patients are diagnosed at an early stage and so the meta-analysis may 
be underpowered to detect differences between early and late stage presentation by SEP. 
In order to conduct meta-analysis it is necessary to compare the odds of advanced stage at diagnosis 
in the most versus the least deprived groups. This necessarily simplifies what may be a complex 
relationship across SEP groups. The ORs used in the meta-analyses were not consistently adjusted 
for the same covariates.  However, we attempted to take this into account in the quality scores and 
by conducting subgroup sensitivity analyses. Examining only high quality studies did not alter 
findings nor did other sensitivity analyses. It may be useful to develop clear guidance on what 
variables should and should not be adjusted for in future analyses to ensure comparability of 
findings. 
Having been unable to find a suitable tool for assessing cohort study quality for a previous review, 
we created our own. Here we adapted our previously developed tool (8) to produce a unique tool 
that is highly specific to detect bias in the type of study included, considering representativeness of 
the sample, measure of independent and outcome variables and confounder adjustment. It is similar 
to a bias assessment checklist tool developed independently in the interim by another review group 
examining time to diagnosis and treatment in cancer (16). 
Many of the studies included in the narrative review were not of high quality. Many studies used 
routine data which rely on accurate routine recording of dates and others included self-report of 
time intervals, which may suffer from recall bias. There is a possibility of ascertainment bias where 
sicker patients may be less likely to have stage data recorded. The ‘waiting time paradox’ where 
sicker patients progress more quickly through the care pathway as they appear more ill (1) was not 
well accounted for and this may mask any true socio-economic inequalities in time intervals (34). 
Lack of consideration of this is a major limitation in the included studies and makes it difficult to 
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draw firm conclusions. Future investigators should routinely include adjustment for patient health 
status. 
Publication bias is a possibility that needs to be considered for any systematic review, as studies 
reporting null findings may be less likely to be published or, if published, to report numerical 
outcomes (62). However, as the majority of the results reported for this review support the null 
hypothesis, further unreported null results would not change the findings.  
Implications for policy and practice 
No inequalities in the patient interval (from symptom recognition to presentation) or in stage at 
diagnosis were found in this review. There is no current evidence that more deprived patients wait 
longer to consult or present with later stage lung cancer. Therefore there is no indication that 
campaigns to improve early diagnosis need to be targeted at specific socio-economic groups. Rather 
that these need to be aimed at everyone with symptoms that might potentially indicate lung cancer. 
However, as more deprived groups have a higher incidence of lung cancer it may still be prudent to 
target campaigns at these groups.  
Results for the referral and diagnostic intervals were inconclusive but there was some suggestion of 
inequalities within these intervals. This could be indicative of clinical bias where, in countries with 
gatekeeping systems, primary care providers may be more actively referring more affluent patients. 
Alternatively, patient ability to navigate through the referral process may vary by SEP (34, 64).  
Future Research 
Although reducing the time to diagnosis and treatment may have important psychological 
implications for all patients (16), evidence for socio-economic inequalities in time to treatment was 
not found. However, many studies did not take factors such as cancer stage and health status into 
account. Better quality studies that attempt to overcome the ‘sicker quicker’ effect by accounting for 
health status and examining early stage patients separately are required, to more clearly determine 
whether inequalities are present. 
Socio-economic inequalities in stage at diagnosis have been suggested as an important explanatory 
factor for survival inequalities in cancer (2). However, socio-economic inequalities in stage at 
diagnosis for lung cancer were not found in UHCSs in the meta-analysis conducted in this review and 
nor was there good evidence for inequalities in time spent on the care pathway. Previous research 
suggests that socio-economic inequalities in lung cancer treatment rather than in time to treatment 
might help explain socio-economic inequalities in lung cancer survival (10). Further investigation of 
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the patient, tumour and system factors that are important determinants of treatment inequalities is 
required.  
CONCLUSIONS 
There is no clear evidence of socio-economic inequalities in stage at diagnosis or time spent within 
intervals on the symptom to treatment pathway for lung cancer. However, the quality of evidence 
available is significantly limited by the failure of most studies to adjust for important potential 
confounders. Results from this review would suggest that inequalities in time to treatment or in 
stage at diagnosis are unlikely to account for known socio-economic inequalities in receipt of 
treatment for, and survival from, lung cancer in UHCSs, but may be present in non-UHCSs.  
 
What is the key question? 
Are there socio-economic inequalities in stage at diagnosis for lung cancer, and in the length of time 
spent on the lung cancer pathway from symptom onset to treatment? 
What is the bottom line? 
There was no evidence of socio-economic inequalities in late stage at diagnosis in the most, 
compared to the least, deprived group nor of inequalities in the patient or treatment intervals, and 
no consistent pattern was observed in diagnostic or referral intervals.  
Why read on? 
Socio-economic inequalities in stage at diagnosis are thought to be an important explanatory factor 
for survival inequalities in cancer. This is the first study to systematically explore the evidence for 
inequalities in stage at diagnosis for lung cancer.  
 
FIGURE LEGENDS 
Figure 1: PRISMA flow diagram 
Figure 2. Likelihood of advanced stage at diagnosis in lowest compared to highest SEP group, by 
healthcare system and overall 
Figure 3: Summary of the review findings for each interval 
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Table S4: Socioeconomic inequalities in stage at diagnosis – studies with data unsuitable for meta-analysis 
Paper Histology Comparison 
N in 
interval % in Q1 % in Q2 % in Q3 % in Q4 % in Q5 P value Further Information 
early stage: 
         
  
Berglund et al 
(2010) 
NSCLC 
% early stage (IA-IIB) compared 
to III-IV 
3272 27.5   26.3   25.1 n/s 
No P but reported 'stage 
distribution did not differ by 
education' 
Hui et al (2005) NSCLC % in stage 1/2 compared to 3/4 398 32 31 13 34 24 0.29 test for linear trend p= 0.85 
Starr et al (2013) NSCLC  
% stage I (a,b) at diagnosis 
compared to stage II/IIIa 
5538 57   58   58 n/s   
Booth et al (2010) NSCLC 
% in stage I  (Q2-5 compared to 
Q1) 
  13 13 0.406   
Forrest et al (2013)  all 
% in stage 1/2 compared to 3/4  
(excluding unstaged) 7769 23.3 23 22.9 22 21.7 0.96 
  
Brewster et al 
(2001) NR 
% with localised stage (compared 
to regional, distant and missing) 3855 28.5   32   36 0.04 
  
Niu et al (2010) 
NR 
% with local stage (compared to 
regional, distant and unknown) 
12237 17 14.2   16.1 15.9 NR women 1986-92 
Niu et al (2010) 
NR 
% with local stage (compared to 
regional, distant and unknown) 
14204 18.1 17.4   16.4 17.9 NR women 1993-99 
Niu et al (2010) 
NR 
% with local stage (compared to 
regional, distant and unknown) 
19540 16.1 14.3   14.9 15.2 NR men 1986-92 
Niu et al (2010) 
NR 
% with local stage (compared to 
regional, distant and unknown) 
18225 15.7 14.9   15 13.5 NR men 1993-99 
Tweed et al (2012) NR % in stage 1/2 compared to 3/4  1190 24   22   22 n/s 
No P but reported 'stage at 
presentation was not different 
based on social deprivation' 
Ghorani et al 
(2012) 
NR 
% in early (stage I-IIIA) compared 
to late (IIIB-IV) 
460 27 27 35 32 28 n/s 
Conf abstract: SEP' not found to 
contribute significantly to stage of 
disease at presentation'  
late stage: 
         
  
Berglund et al 
(2010) 
NSCLC 
% late stage (III/IV) compaed to 
IA-IIB 
3272 72.5   73.7   74.9 n/s 
No P but reported 'stage 
distribution did not differ by 
education' 
Booth et al (2010) NSCLC 
% in stage IV  (Q2-5 compared to 
Q1) 
  47 49 0.204   
Pagano et al (2010) NSCLC % of late stage at diagnosis 1878 47.3   42.7   45.0 NR by education 
Hui et al (2005) NSCLC % stage 3/4 compared to 1/2 398 68 69 87 66 76 0.29 test for linear trend p= 0.85 
Deepak et al 
(2012) 
all % with late stage at diagnosis 
  
48.5       51 NR late stage not clearly defined 
Forrest et al (2013) all % in stage 3/4 7769 76.7 77 77.1 78 78.3 0.96   
Tweed et al (2012) NR % in stage 3/4 compared to 1/2 1190 76   78   78 n/s 
No P but reported 'stage at 
presentation was not different 
based on social deprivation' 
Ghorani et al 
(2012) 
NR 
% in late (IIIB-IV) compared to 
early (stage I-IIIA)  
460 73 73 65 68 72 n/s 
Conf abstract: SEP 'not found to 
contribute significantly to stage of 
disease at presentation'  
Brewster et al 
(2001) NR 
% distant stage (compared to 
localised, regional and missing) 3855 34.3   30.6   31.1 0.04 
  
No numbers presented:                   
Cheyne et al 
(2013) 
NSCLC 
proportion in each stage, by SEP 
1432           0.98 
No significant differences between 
the 5 quintiles' but no numbers 
reported. Univariable analysis 
Gong et al (2012) NR 
higher % of late stage lung 
cancer correlated with higher 
deprivation    
          p<0.005 
mean weighted summary stat 
reported 
Johnson et al 
(2014) 
NSCLC 
likelihood of later stage at 
diagnosis in lower and higher SEP 
32711           n/s 
No numbers presented. Adjusted 
for grade, age, sex, race. 'No sig 
relationship between social 
environment and late stage disease 
(results not shown)' 
SCLC 
         
  
Hui et al (2005) SCLC extensive 78 71 100 62 67 42 0.28 test for linear trend p= 0.07 
subdivided by race: 
         
  
Haas et al (2008) NR 
Early stage diagnosis by SEP area 
(income), in high or low racially 
segregated areas 
81508           n/s 
black v white, hispanic v white. No 
disparities in stage in low 
segregation/high income (most 
advantaged) compared to high 
segregation/low income (most 
disadvantaged) 
univariable OR: 
     
 
   
  
Paper Histology Comparison 
N in 
interval 
OR (CI) in Q1 OR (CI) in Q2 OR (CI) in Q3 OR (CI) in Q4 OR (CI) in Q5 P value 
Further Information 
Slatore et al (2011) NSCLC 
OR (95% CI of advanced stage at 
diagnosis 612 
1.66 (1.00-
2.76)       1.00 0.048 
univariable analysis  
Slatore et al (2011) NSCLC 
OR (95% CI of advanced stage at 
diagnosis 612 
1.04 (0.67-
1.62)       1.00 NR 
univariable analysis, n/s 
 
  
Table S5: Socioeconomic inequalities in stage at diagnosis – studies with data considered for meta-analysis 
Paper Country 
Years of 
Diagnosis 
Histolo
gy 
Comparison 
Measure of 
SEP 
N of 
SEP 
grps 
N 
OR (CI) 
in Q1 
OR (CI) in 
Q2 
OR (CI) in 
Q3 
OR (CI) in 
Q4 
OR (CI) 
in Q5 
P 
value 
Further 
Informatio
n 
OR (CI) of 
late stage 
disease in 
lowest 
SEP group 
compared 
to highest 
Ghorani et al 
(2012) 
England 
2005-
2011 
NR 
Likelihood of 
advanced 
stage at 
diagnosis in 
lower 
compared to 
high SEP 
Income 
domain of 
IMD 2010 
5 460 1.00 
1.01 (0.52 
to 1.95) 
0.70 (0.41 
to 1.19) 
0.90 
(0.53 to 
1.51) 
1.11 
(0.67 to 
1.87) 
0.72   
1.11 (0.67 
to 1.87) 
Lyratzopoulos 
et al (2012) 
England 
2006-
2009 
NSCLC 
Likelihood of 
advanced 
stage at 
diagnosis in 
lower 
compared to 
high SEP 
Income 
domain of 
IMD 2004 
5 10435 1.00 
0.94 (0.81 
to 1.09) 
0.97 (0.83 
to 1.12) 
0.98 
(0.84 to 
1.14) 
0.81 
(0.66 to 
0.99) 
0.29 
log 
likelihood p 
0.81 (0.66 
to 0.99) 
Lyratzopoulos 
et al (2013) 
England 
2006-
2010 
NSCLC 
Likelihood of 
advanced 
stage at 
diagnosis in 
lower 
compared to 
high SEP 
Income 
domain of 
IMD 2004 
5 16714 1.00 
0.97 (0.94 
to 1.01) 
0.95 (0.88 
to 1.01) 
0.92 
(0.83 to 
1,02) 
0.89 
(0.78 to 
1.03) 
0.109 Wald test p 
0.89 (0.78 
to 1.03) 
Silverstein et 
al (2002) 
USA 
1991-
1995 
NSCLC 
Likelihood of 
distant stage 
at diagnosis 
in lower 
compared to 
high SEP 
Per capita 
income and 
education 
2 3040 1.00       
1.06 
(0.28 to 
3.96) 
n/s P NR 
1.06 (0.28 
to 3.96) 
Dalton et al 
(2011) 
Denmark 
2001-
2008 
all 
likelihood of 
later stage at 
diagnosis in 
higher 
compared to 
low SEP 
Education 3 16713 
0.92 
(0.84 
to 
0.99) 
  
0.99 (0.93 
to 1.06) 
  1.00 0.08 p for trend 
1.09 (1.01 
to 1.19)  
Dalton et al 
(2011) 
Denmark 
2001-
2008 
all 
Likelihood of 
non-localised 
stage in 
Income 3 16713 
0.99 
(0.89 
to 
  
1.05 (0.98 
to 1.11) 
  1.00 0.81 p for trend 
1.01 (0.90 
to 1.12)  
higher 
compared to 
low SES 
1.11) 
Schwartz et al 
(2003) 
USA 
1988-
1992 
all 
Likelihood of 
non-localised 
stage in 
higher 
compared to 
low SES 
Aggregate 
SES 
variable 
using 
occupation, 
poverty, 
education 
and age 
4 12895 
0.78 
(0.69 
to 
0.89) 
0.76 (0.66 
to 0.87) 
  
0.79 
(0.69 to 
0.91) 
1.00 NR 
P 
significant 
but NR 
1.28 (1.12 
to 1.45) 
Berglund et al 
(2012) 
England 
2006-
2008 
NSCLC 
Likelihood of 
early stage 
disease in 
lower 
compared to 
high SEP 
Income 
domain of 
IMD 2007  
5 1918 1.00 
1.24 (1.04 
to 1.49) 
1.11 (0.93 
to 1.33) 
1.18 
(1.00 to 
1.40) 
1.01 
(0.85 to 
1.20) 
0.44 p for trend 
0.99 (0.83 
to 1.18) 
Stevens et al 
(2008) 
New 
Zealand 
2004 NSCLC 
Likelihood of 
having 
localised 
disease in 
high 
compared to 
low 
deprivation 
NZ 
Deprivation 
Index 2001 
5 491 1.0 
1.2 (0.6-
2.6) 
1.6 (0.8-
3.2) 
0.8 (0.4 
to 1.7) 
0.9 (0.4 
to 1.7) 
0.5, 
0.21, 
0.63, 
0.65 
  
1.11 (0.59 
to 2.50) 
 
  
Table S7: Socioeconomic inequalities in time from symptom recognition to presentation, referral or diagnosis 
Paper Interval 
N in 
interval 
Histology Delay measure 
Median 
Time 
IQR Q1 Q2 Q3 Q4 Q5 Q6 Q7 Q8 
P 
value 
Further 
Information 
Mor et al 
(1990) 
symptom 
recognition to 
first 
presentation 
97 any 
% of patients delaying for 
longer than 3 months, by 
education 
    
12.5% 31.6% 25.6% 10%       
  
p>0.05 
age, sex, support 
network, stage, 
co-morbidity not 
significant 
Mor et al 
(1990) 
symptom 
recognition to 
first 
presentation 
97 any 
% of patients delaying for 
longer than 3 months in 
low and high SES  
    
19.2% 
      
23.8%     
  
p>0.05 
age, sex, support 
network, stage, 
co-morbidity not 
significant 
Smith et 
al (2009) 
symptom to 
present 
(checklist) 
330 any 
Median time (IQR) to 
consultation, by SEP 
99 
31-
381 
87.1 
(52.0 
to 
145.8) 
109.6 
(71.2 
to 
169.0) 
109.6 
(67.8 
to 
177.2) 
81.3 
(46.3 
to 
142.8) 
93.3 
(66.4 
to 
131.2) 
          
Smith et 
al (2009) 
symptom to 
present 
(patient) 
333 any 
Median time (IQR) to 
consultation, by SEP 
21 7-56 
21.4 
(13.9 
to 
33.0) 
22.4 
(15.9 
to 
31.6) 
20.4 
(13.3 
to 
31.4) 
14.1 
(8.8t o 
22.6) 
16.6 
(12.4 
to 
22.1) 
          
Neal et al 
(2005) 
symptom to 
referral 
3260 any mean time (sd) by SEP 
    
73 
(105) 
74 
(134) 
59 
(91) 
87 
(330) 
83 
(238) 
122 
(596) 
45 
(20) 
85 
(321) 
  
univariable 
analysis 
Neal et al 
(2005) 
symptom to 
diagnosis 
2669 any mean time (sd) by SEP 
    
91 
(124) 
85 
(141) 
74 
(99) 
95 
(332) 
91 
(227) 
101 
(350 
55 
(35) 
106 
(356) 
  
univariable 
analysis 
 
  
Table S8: Socioeconomic inequalities in time from referral to first hospital appointment, diagnosis or treatment 
Paper Interval 
No in 
interval 
Histology Delay measure 
Median 
Time 
IQR 
Time 
(IQR) in 
Q1 
Time 
(IQR) in 
Q2 
Time 
(IQR) in 
Q3 
Time 
(IQR) in 
Q4 
Time 
(IQR) in 
Q5 
P 
value 
Extra info 
Time 
(IQR) 
in Q6 
Time 
(IQR) 
in 
Q7 
Time 
(IQR) 
in 
Q8 
Neal et al (2005) 
referral to 
FHA 
2950 any mean time (sd) 
  
  30 (48) 36 (54) 36 (51) 33 (47) 33 (47) n/s univariable 
30 
(51) 
130 
(121) 
37 
(49) 
Forrest et al 
(2014) 
referral to 
FHA 
14730 all 
median time in 
days (IQR) 
10 6-17 9 (5-15) 10 (6-17) 10 (6-17) 11 (6-18) 10 (6-17) NR univariable 
 
  
Paper Interval 
No in 
interval 
Histology 
Delay measure 
statistics 
Median 
Time 
IQR 
OR/HR 
(CI) inQ1 
OR/HR 
(CI) in 
Q2 
OR/HR 
(CI) in 
Q3 
OR/HR 
(CI) in 
Q4 
OR/HR 
(CI) in 
Q5 
P 
value 
Further 
Information 
   
Forrest et al 
(2014) 
referral to 
FHA 
14730 all 
OR of likelihood of 
FHA within 14 days 
of referral in lower 
compared to 
highest SEP 
10 6-17 1.00 
0.85 
(0.74 to 
0.99) 
0.81 
(0.70 to 
0.99) 
0.75 
(0.66 to 
0.86) 
0.83 
(0.73 to 
0.94) 
0.001 
age, 
histology, 
year of 
diagnosis, 
stage, PS 
   
Paper Interval 
No in 
interval 
Histology Delay measure 
Median 
Time 
IQR 
Time 
(IQR) in 
Q1 
Time 
(IQR) in 
Q2 
Time 
(IQR) in 
Q3 
Time 
(IQR) in 
Q4 
Time 
(IQR) in 
Q5 
P 
value 
Further 
Information 
   
Berglund et al 
(2010) 
referral to 
diagnosis  
841 
NSCLC 
(early 
stage) 
time in days 
  
  17       32 NR univariable 
   Berglund et al 
(2010) 
referral to 
diagnosis  
2431 
NSCLC 
(late 
stage) 
time in days 
  
            n/s 
univariable, 
numbers not 
reported 
   Dalton et al 
(2011) 
referral to 
diagnosis  
18103 all?? time in days 20   20   20   21 NR univariable 
   Forrest et al 
(2014) 
referral to 
diagnosis 
14860 all 
median time in 
days (IQR) 
13 7-24 13 (7-21) 13 (7-24) 13 (7-25) 14 (7-25) 13 (7-23) NR univariable 
   
Paper Interval 
No in 
interval 
Histology Delay measure     
% not 
delayed 
in Q1 
% not 
delayed 
in Q2 
% not 
delayed 
in Q3 
% not 
delayed 
in Q4 
% not 
delayed 
in Q5 
P 
value 
Further 
Information 
   Starr et al 
(2013) 
referral to 
diagnosis 
5538 
NSCLC (I-
IIIa) 
% with ref to diag 
<=28 days   
  55   55   51 NR univariable 
   
Paper Interval 
No in 
interval 
Histology 
Delay measure 
statistics 
    
OR(CI) 
inQ1 
OR (CI) 
in Q2 
OR (CI) 
in Q3 
OR/HR 
in Q4 
OR (CI) 
in Q5 
P 
value 
Further 
Information 
   
Dalton et al 
(2011) 
referral to 
diagnosis  
5992 
all/NSCLC? 
(early 
stage) 
OR of likelihood of 
diagnosis > 28 days 
after referral in 
higher compared to 
low education   
  
0.82 
(0.70 to 
0.96) 
  
0.87 
(0.81 to 
0.94) 
  1.00 <0.001 
age, sex, 
income, 
cohab, CCI 
not sig. P for 
trend. 
   
Dalton et al 
(2011) 
referral to 
diagnosis  
5992 
all/NSCLC? 
(early 
stage) 
OR of likelihood of 
diagnosis > 28 days 
after referral in 
higher compared to 
low income   
  
0.85 
(0.74 to 
0.98) 
  
0.94 
(0.84 to 
1.06) 
  1.00 0.06 
age, sex, 
educ, cohab, 
CCI not sig. P 
for trend 
   
Dalton et al 
(2011) 
referral to 
diagnosis  
10721 
all/NSCLC? 
(late 
stage) 
OR of likelihood of 
diagnosis > 28 days 
after referral in 
higher compared to 
low education   
  
0.82 
(0.72 to 
0.93) 
  
0.97 
(0.89 to 
1.05) 
  1.00 0.01 
age, sex, CCI 
sig. P for 
trend. 
   
Dalton et al 
(2011) 
referral to 
diagnosis  
10721 
all/NSCLC? 
(late 
stage) 
OR of likelihood of 
diagnosis > 28 days 
after referral in 
higher compared to 
low income   
  
0.93 
(0.83 to 
1.03) 
  
1.02 
(0.92 to 
1.12) 
  1.00 0.20 
age, sex, 
educ, CCI sig. 
P for trend 
   
Forrest et al 
(2014) 
referral to 
diagnosis 
14860 all 
OR of likelihood of 
diagnosis within 31 
days of referral in 
lower compared to 
highest SEP 
    1.00 
0.90 
(0.76 to 
1.07) 
0.84 
(0.71 to 
0.99) 
0.83 
(0.71 to 
0.97) 
0.93 
(0.80 to 
1.08) 
0.11 
sex, 
histology, 
year of 
diagnosis, 
stage, PS, 
treatment 
   
Paper Interval 
No in 
interval 
Histology Delay measure 
Median 
Time 
IQR 
Time 
(IQR) in 
Q1 
Time 
(IQR) in 
Q2 
Time 
(IQR) in 
Q3 
Time 
(IQR) in 
Q4 
Time 
(IQR) in 
Q5 
P 
value 
Further 
Information  
  Campbell et al 
(2002) 
referral to 
treatment 
653 all 
median time in 
days (IQR) 
34   
33 (15 to 
104) 
38 (11 to 
78) 
39 (17 to 
81) 
42 (16 to 
121) 
25 (13 to 
77) 
NR univariable 
   Forrest et al 
(2014) 
referral to 
treatment 
10090 all 
median time in 
days (IQR) 
56 
39-
79 
54 (36-
75) 
55 (38-
79) 
56 (39-
80.5) 
56 (38-
79) 
56 (39-
79) 
NR univariable 
 
  
Paper Interval 
No in 
interval 
Histology 
Delay measure 
statistics 
Median 
Time 
IQR 
OR/HR 
(CI) in 
Q1 
OR/HR 
(CI) in 
Q2 
OR/HR 
(CI) in 
Q3 
OR/HR 
(CI) in 
Q4 
OR/HR 
(CI) in 
Q5 
P 
value 
Further 
Information 
   
Campbell et al 
(2002) 
referral to 
treatment 
653 all 
OR of likelihood of 
treatment within 
56 days of referral 
in lower compared 
to highest SEP 
34   1.00 
1.12 
(0.79 to 
1.59) 
1.08 
(0.78 to 
1.51) 
0.94 
(0.68 to 
1.30) 
1.07 
(0.78 to 
1.49) 
0.813 
P for trend. 
HR 
   
Forrest et al 
(2014) 
referral to 
treatment 
10090 all 
OR of likelihood of 
treatment within 
62 days of referral 
in lower compared 
to highest SEP 
56 
39-
79 
1.00 
0.89 
(0.75 to 
1.05) 
0.84 
(0.71 to 
0.98) 
0.80 
(0.69 to 
0.94) 
0.88 
(0.76 to 
1.01) 
0.08 62 day target 
    
  
Table S9: Socioeconomic inequalities in time from first hospital appointment to diagnosis 
Paper Interval 
No in 
interval 
Histology Delay measure 
Median 
Time 
IQR 
OR (CI) 
inQ1 
OR (CI) 
in Q2 
OR (CI) 
in Q3 
OR 
(CI) in 
Q4 
OR (CI) 
in Q5 
P 
value 
Further 
Information 
   
Forrest et al 
(2014) 
FHA to 
diagnosis 
28284 all 
OR of likelihood of 
diagnosis within 17 
days of referral in 
lower compared to 
highest SEP 
0 0-0 1.00 
0.89 
(0.75 
to 
1.07) 
0.87 
(0.74 to 
1.02) 
0.90 
(0.77 
to 
1.07) 
0.92 
(0.80 
to 
1.07) 
0.50 
adjusted for 
histology, year of 
diagnosis, stage, 
PS, treatment 
   
Paper Interval 
No in 
interval 
Histology Delay Measure 
Median 
Time 
IQR/
SE 
Time 
(IQR) in 
Q1 
Time 
(IQR) in 
Q2 
Time 
(IQR) in 
Q3 
Time 
(IQR) 
in Q4 
Time 
(IQR) 
in Q5 
P 
value 
Further 
Information 
Time 
(IQR) 
in 
Q6 
Time 
(IQR) 
in 
Q7 
Time 
(IQR) 
in Q8 
Neal et al 
(2005) 
FHA to 
diagnosis 
3199 any 
mean time in days 
(sd)   
  17 (31) 11 (22) 14 (25) 
12 
(24) 
11 (22) NR   
13 
(24) 
9 
(11) 
13(24) 
Yorio et al 
(2009) 
image to 
diagnosis (by 
education) 
345 
NSCLC 
(stage I-
III) 
median time in 
days (IQR)  
  
  
17 (8-
37) 
16 (6-
39) 
  
13 (5-
33) 
21 (5-
61) 
0.63 
SEP measured by 
education 
   
Yorio et al 
(2009) 
image to 
diagnosis (by 
income) 
345 
NSCLC 
(stage I-
III) 
median time in 
days (IQR)  
  
  
16 (8-
30) 
18 (6-
46) 
  
14 (7-
39) 
19 (4-
50) 
0.27 
SEP measured by 
income 
   
                  
  
Table S10: Socioeconomic inequalities in time from diagnosis to treatment 
Paper Interval 
No in 
interva
l 
Histolog
y 
Delay measure 
Median/ 
Mean 
Time 
IQR/SE 
OR/HR (CI) 
inQ1 
OR/HR (CI) 
in Q2 
OR/HR (CI) 
in Q3 
OR/HR 
(CI) in Q4 
OR/HR 
(CI) in Q5 
P value Further Information 
Shin et 
al 
(2013) 
diagnosis 
to 
surgery 
398 
NSCLC 
(early 
stage?) 
HR (95% CI) of delayed 
time (weeks) to 
surgery in higher 
compared to low 
income 
20/30 
1-302/ 
38.0 
0.94 (0.71 
to 1.23) 
  
1.10 (0.86 
to 1.42) 
  1.00 n/s   
Forrest 
et al 
(2014) 
diagnosis 
to 
treatmen
t 
15373 all 
OR (95% CI) of 
likelihood of treatment 
within 31 days of 
diagnosis in lower 
compared to high SEP 
36 22-56 1.00 
0.97 (0.85 
to 1.11) 
0.89 (0.78 
to 1.01) 
0.94 
(0.84 to 
1.06) 
0.91 
(0.81 to 
1.02) 
0.29 
age, histology, year of 
diagnosis, stage, PS, 1st 
treatment significant 
Paper Interval 
No in 
interva
l 
Histolog
y 
Delay measure 
Median 
Time 
IQR/SE 
Time (IQR) 
in Q1 
Time (IQR) 
in Q2 
Time (IQR) 
in Q3 
Time 
(IQR) in 
Q4 
Time 
(IQR) in 
Q5 
P value Further Information 
Forrest 
et al 
(2014) 
diagnosis 
to 
treatmen
t 
15373 all 
median time in 
days(IQR) 
36 22-56 35 (21-55) 35 (21-56) 36 (22-57) 
36 (22-
56) 
36 (22-
56) 
NR   
Halper
n et al 
(2012) 
diagnosis 
to 
treatmen
t 
32899 all time in months               n/s 
No numbers given but 
reported that income and 
census tract education level 
not associated with delay 
Saint-
Jacque
s et al 
(2008) 
detection 
to 
surgery 
(by 
income) 
102 
NSCLC 
(stage I-
III) 
time in days 107 73-141           0.053 
by income.n/s P reported but 
no numbers shown by income. 
'Shorter time with higher 
income' 
Saint-
Jacque
s et al 
(2008) 
detection 
to 
surgery 
consult 
(by 
educatio
n) 
107 
NSCLC 
(stage I-
III) 
geometric mean 
number of days (95% 
CI) 
45 22-72 37 (29-48)       
50 (37-
68) 
0.127 by education 
Yorio 
et al 
(2009) 
diagnosis 
to 
treatmen
t (by 
educatio
n) 
301 
NSCLC 
(stage I-
III) 
median time in days 
(IQR) 
    30 (20-52) 32 (15-53)   
38 (20-
54) 
34 (20-
56) 
0.68 by education 
Yorio 
et al 
(2009) 
diagnosis 
to 
treatmen
t (by 
income) 
301 
NSCLC 
(stage I-
III) 
median time in days  
(IQR) 
    29 (17-55) 32 (20-49)   
35 (15-
62) 
36 (21-
56) 
0.27 by income 
 
  
Table S11: Socioeconomic inequalities in proxy measures of delay 
Paper Measure N Histology 
OR/HR (CI) 
inQ1 
OR/HR (CI) in 
Q2 
OR/HR (CI) in 
Q3 
OR/HR (CI) in 
Q4 
OR/HR (CI) 
in Q5 
P value 
Other 
significant 
variables 
Further Information 
Beckett et al 
(2012) 
acute presentation 100864 NSCLC 1.00 
1.02 (0.96 to 
1.08) 
0.99 (0.93 to 
1.06) 
1.09 (1.02 to 
1.16) 
1.06 (1.00 
to 1.13) 
NR 
age, stage, 
PS 
  
Beckett et al 
(2014) acute presentation 
133530 
NSCLC 
0.92 (0.87 to 
0.96) 
0.91 (0.86 to 
0.95) 
0.94 (0.89 to 
0.98) 
1.02 (0.97 to 
1.07) 1.00 
0.001, 
<0.001, 
0.009, 
0.418 
age, stage, 
PS overall p not reported 
Raine et al 
(2010) 
emergency 
admission 
(patient) 
186741 all 
0.64 (0.62 to 
0.67) 
0.68 (0.66 to 
0.71) 
0.74 (0.72 to 
0.76) 
0.80 (0.78 to 
0.82) 
1.00 <0.001 
sex, age, 
admission 
period   
Pollock&Vickers 
(1998) 
emergency 
admission 
38668 
all 
1.00 
1.16 (1.04 to 
1.28) 
1.38 (1.24 to 
1.52) 
1.61 (1.46 to 
1.78) 
2.20 (1.99 
to 2.43) <0.05   adjusted for age and sex 
Abel et al 
(2015) 
emergency 
presentation 
62498 
  
          
NR   
graph showing higher 
odds of emergency 
presentation in more 
deprived - no numbers 
presented 
McPhail et al 
(2013) 
emergency 
presentation 
9601 any 1.0 1.0 (0.9 to 1.2) 1.2 (1.0 to 1.3) 
1.3 (1.1 to 
1.5) 
1.4 (1.2 to 
1.6) 
NR 
sex, stage, 
age, co-
morbidity 
  
Jones et al 
(2010) 
diagnosis at death 36947 all 
1.001 (0.998 
to 1.004) 
        p>0.05     
Smith et al 
(2009) 
OR (CI) of number 
of times to consult 
in highest SEP 
compared to 
lowest 
330 any         
0.99 (0.85 
to 1.17) 
0.885 ?? 
symptom to present 
(using checklist) 
Smith et al 
(2009) 
OR (CI) of number 
of times to consult 
in highest SEP 
compared to 
lowest 
333 any 
1.00 (0.85 to 
1.17) 
        0.986 ?? 
symptom to present 
(patient reported) 
 
Table S1 – Included studies (n=39) 
Paper Country Data Source (s) N 
Years of 
Diagnosis 
Outcome - stage at 
diagnosis/Interval/ proxy 
measure 
Comparison Measure of SEP 
N of SEP 
groups 
Multivari
able 
analysis? 
Quality 
Score 
Abel et al (2015) England 
National Cancer Data 
Repository 
162543 
2006-
2010 
emergency presentation 
likelihood of emergency 
presentation in lower 
compared to high SEP 
IMD 2010, income domain 5 
Yes 2 
Beckett et al* 
(2012) 
England LUCADA 100884 NR acute presentation 
likelihood of acute 
presentation in lower 
compared to high SEP 
IMD 5 
Yes 7 
Beckett et al 
(2014) 
England LUCADA 133530 
2006-
2011 
acute presentation 
likelihood of acute 
presentation in higher 
compared to low SEP 
IMD 5 
Yes 7 
Berglund et al 
(2010) 
Sweden 
 RLCR- Sweden, Cause of 
Death Register and LISA 
(insurance and 
demographics) 
3369 
1996-
2004 
referral to diagnosis, 
stage at diagnosis 
waiting time in highest and 
lowest SEP 
SEI, household income, 
education level 
3 
No 2 
Berglund et al 
(2012) 
England Thames Cancer Registry 15582 
2006-
2008 
stage at diagnosis 
odds of early stage disease in 
lower compared to high SEP 
IMD 2007, income domain 5 Yes 8 
Booth et al 
(2010) 
Canada Ontario Cancer Registry 12276 
2003-
2007 
Stage at diagnosis 
Proportion with stage I and 
stage IV, in lower compared to 
highest SEP 
Community median 
household income 
5 No  2 
Brewster et al 
(2001) 
Scotland 
Scottish Cancer Registry 
and medical records 
3855 1999 Stage at diagnosis 
% with localised, regional and 
distant stage in affluent (1-2), 
middle (3-5) and deprived (6-7) 
patients 
Carstairs Index 3 No 2 
Campbell et al 
(2002) 
Scotland 
Scottish Cancer Registry 
and  hospital case notes 
653 
1995-
1996 
first referral to first 
treatment 
HR of quicker treatment in 
lower compared to highest SEP 
Carstairs Index 5 Yes 6 
Cheyne et al 
(2013) 
England 
Leeds Teaching Hospital 
NHS Trust e-health records 
1432 
2008-
2010 
stage at diagnosis 
proportion in each stage, by 
SEP 
IMD and ACORN tool 5 No 1 
Dalton et al 
(2011) 
 
Denmark 
Danish Lung Cancer 
Registry 
16713 
2001-
2008 
referral to diagnosis, 
stage at diagnosis 
likelihood of diagnosis >28 
days after referral (or of later 
stage at diagnosis) in higher 
compared to low SEP 
education or income 3 Yes 7 
Deepak et al * 
(2012) 
USA SEER-linked Medicare NR 
2001-
2005 
stage at diagnosis 
likelihood of late stage at 
diagnosis in low v high SEP 
patients 
census tract level median 
household income 
3 No 2 
Forrest et al 
(2013) 
England 
NYCRIS cancer registry, 
HES and LUCADA 
28733 
2006-
2010 
Stage at diagnosis 
likelihood of late stage 
diagnosis in lower compared to 
high SEP 
income domain of IMD 
2004 & 2007 
5 No 2 
Forrest et al 
(2014) 
England 
NYCRIS cancer registry, 
HES and LUCADA 
28733 
2006-
2010 
referral to FHA, referral to 
diagnosis, referral to 
treatment, FHA to 
diagnosis, diagnosis to 
treatment 
likelihood of referral, diagnosis 
and treatment within target 
time for interval, in low 
compared to highest SEP 
income domain of IMD 
2004 & 2007 
5 Yes 8 
Ghorani et 
al*(2012) England 
LUCADA (1 East London 
hospital) 
460 
2005-
2011 
stage at diagnosis 
likelihood of late stage 
diagnosis in lower compared to 
high SEP 
Income domain of IMD 
2010 
5 
No 2 
Gong et al (2012) USA Texas Cancer Registry NR 
1997-
2003 
stage at diagnosis stage at diagnosis by county WI Wellbeing Index  NR Yes 1 
Haas et al (2008) USA SEER linked to Medicare 81508 
1992-
2002 
stage at diagnosis 
early stage diagnosis by SEP 
area, in black compared to 
white 
Area-based measure of 
segregation and income 
4 Yes 3 
Halpern et al 
(2012) 
USA SEER-Medicare claims data 32899 
2000-
2002 
diagnosis to first 
treatment 
likelihood of being in top 5% of 
time from diagnosis to first 
treatment 
median household income 
(ZIP code) 
NR No 1 
Hui et al (2005) Australia NSW Cancer Registry 476 1996 stage at diagnosis 
% with late (3B/4) stage at 
diagnosis 
SEIFA IRSD (socio-
economic index for areas 
1996 index of relative 
socio-economic 
disadvantage) 
5 No 2 
Johnson et al 
(2014) 
USA 
Georgia Comprehensive 
Cancer Registry  
57120 
2000-
2009 
Stage at diagnosis 
Likelihood of late stage at 
diagnosis 
Composite measure of 
economic deprivation and 
educational attainment 
4 Yes 2 
Jones et al (2010) England NYCRIS Cancer Registry 36947 
1994-
2002 
diagnosis at death 
OR of diagnosis at death as 
deprivation increased 
IMD (with access to 
services 'geographical 
barriers'  sub domain 
removed) 
1 Yes 6 
Lyratzopoulos et 
al (2012) 
England 
Eastern Cancer Registry 
and Information Centre 
(ERCIC) 
13286 
2006-
2009 
stage at diagnosis 
Likelihood of advanced stage at 
diagnosis in lower compared to 
high SEP 
Income domain of IMD 
2004 
5 Yes 7 
Lyratzopoulos et 
al (2013) 
England 
Eastern Cancer Registry 
and Information Centre 
(ERCIC) 
16714 
2006-
2010 
stage at diagnosis 
Likelihood of advanced stage at 
diagnosis in lower compared to 
high SEP 
income domain of IMD 
2004 
5 Yes 7 
McPhail et al 
(2013) 
England 
Eastern Cancer Registry 
and Information Centre 
(ERCIC) 
9601 
2006-
2008 
emergency presentation 
likelihood of emergency 
presentation in lower 
compared to high SEP 
income domain of IMD 
2007 
5 Yes 7 
Mor et al (1990) USA 
hospital records/database 
and patient interview 
97 
1984-
1986 
patient (symptom 
recognition to first 
presentation) 
% of patients delaying for 
longer than 3 months in low 
and high SEP and by education 
SEP (low and middle/high) 
and education (4 
categories) 
2 No 2 
Neal et al (2005) England 
National Survey of NHS 
patients: Cancer 
3260 2002? 
total (symptom to 
diagnosis), pre-
hospital(symptom to GP), 
referral (GP to FHA), 
secondary care (FHA to 
diagnosis) 
mean delay (sd) in each SEP 
group 
Registrar General 
classification: Prof, 
Man/Tech, skilled non-
man, skilled man, part 
skilled, unskilled, armed 
forces, never worked 
8 Yes 3 
Niu et al (2010) USA 
New Jersey State Cancer 
Registry 
64206 
1986-
1999 
stage at diagnosis 
% with local stage at diagnosis 
by sex, and within this by 
poverty level (for 2 time 
periods) 
residence census tract 
poverty rate 
4 No 2 
Pagano et al 
(2010) 
Italy 
Piedmont Cancer Registry 
of Turin 
2259 
2000-
2003 
stage at diagnosis 
N (%) of early or late stage at 
diagnosis, by education level 
education level 3 No 2 
Pollock&Vickers 
(1998) England HES FCEs 38668 
1992-
1995 
Emergency admission OR of emergency admission in 
lower compared to highest SEP 
Townsend 10 Yes 4 
Raine et al (2010) England HES FCEs 186741 
1999-
2006 
emergency admission OR of emergency admission in 
higher compared to lowest SEP 
IMD 5 Yes 5 
Saint-Jacques et 
al (2008) 
Canada 
Nova Scotia Cancer 
Registry database 
(Oncology Patient 
Information Centre) 
108 2005 
detection to surgery, 
detection to surgery 
consult, 
surgery to adjuvant 
wait time in low and high 
education/income groups 
Education and income 2 Yes 6 
chemo, 
detection to adjuvant 
chemo 
Schwartz et al 
(2003) 
USA 
Metropolitan Detriot 
Cancer Surveillance 
System (MDCSS) cancer 
registry (SEER) 
12895 
1988-
1992 
stage at diagnosis 
likelihood of non-localised 
stage in higher compared to 
low SES 
SEP (aggregate variable 
using occupation, poverty, 
education and age) 
4 Yes 6 
Shin et al (2013) 
 
Korea 
Korean Central Cancer 
registry (KCCR) 
398 
2003-
2005 
diagnosis to surgery 
HR of delayed time to surgery 
in higher compared to low 
income, for early stage NSCLC 
patients 
income status 3 Yes 7 
Silverstein et al 
(2002) 
USA 
Savannah River Regional 
Health Information System 
(SRRHIS) cancer registry 
3477 
1991-
1995 
stage at diagnosis 
likelihood of distant stage at 
diagnosis in lower compared to 
high SEP 
per capita income and 
education 
2 Yes 6 
Slatore et al 
(2011) 
USA 
Vitamins and Lifestyle 
(VITAL) prospective cohort 
study and SEER data 
612 
2000-
2007 
stage at diagnosis 
likelihood of advanced stage at 
diagnosis compared to early 
stage, by SEP 
education and income 2 Yes 2 
Smith et al (2009) Scotland 3 Scottish hospitals 360 
2004-
2006 
patient defined first 
symptom to first consult, 
earliest checklist 
symptom to first consult 
number of times longer to 
consult GP in lower SEP 
compared to high 
Carstairs Index (and 
education) 
5 Yes 4 
Starr et al (2013) Denmark 
Danish Lung Cancer 
Register linked to 
Integrated Database for 
Labour Market research 
and the Danish Hospital 
Discharge Register 
5538 
2001-
2008 
referral to diagnosis, 
stage at diagnosis 
N and % with time between 
referral and diagnosis <= 28 
days,  and >28 days, in short, 
medium and high education 
education 3 No 2 
Stevens et al 
(2008) 
New 
Zealand 
regional hospital and 
oncology databases 
checked against NZ Cancer 
Registry data 
565 2004 Stage at diagnosis 
likelihood of having localised 
disease in high compared to 
low deprivation 
NZ Deprivation Index 2001 5 Yes 7 
Tweed et al* 
(2012) 
Scotland Scottish Cancer registry 1190 
2009-
2010 
Stage at presentation 
stage at presentation in lower 
compared to high SEP 
DEPCAT index of 
deprivation 
3 No 2 
Yorio et al (2009) USA 
University of Texas 
Southwestern Medical 
Center 
482 
2000-
2005 
image to diagnosis, 
diagnosis to treatment, 
image to treatment, 
diagnosis to death 
median time (IQR) in each 
income and education quartile 
Income and education 4 Yes 6 
 
* Conference abstract only, not full paper 
ACORN = A Classification of Residential Neighbourhoods, HES = Hospital Episode Statistics, HES FCEs = HES finished consultant episodes, HR = hazard ratio, 
IMD = Index of Multiple Deprivation, LUCADA = Lung cancer audit data, NHS = National Health Service, NR = not reported, NSW = New South Wales, NYCRIS 
= Northern and Yorkshire Cancer Registry and Information Service, NZ = New Zealand, OR = odds ratio, RLCR = Regional Lung Cancer Register, SD = standard 
deviation, SEER = Surveillance, Epidemiology and End Results programme, SEI = Socioeconomic Index, SEP = socio-economic position, WI = Wellbeing Index 
 
